<span class="paragraphSection"><strong>Background.</strong> Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) was introduced to adult anaesthesia to improve the safety of airway management during apnoea before intubation. The objective of our study was to determine whether THRIVE safely prolongs apnoeic oxygenation in children.<strong>Methods.</strong> This was a randomized controlled trial in 48 healthy children, with normal airways and cardiorespiratory function, in age groups 0–6 and 7–24 months, 2–5 and 6–10 yr old, presenting for elective surgery or imaging under general anaesthesia. All children were induced with sevoflurane, O<sub>2</sub>, and N<sub>2</sub>O, followed by muscle relaxation with rocuronium, and standardized preoxygenation with bag-and-mask ventilation. The control arm received jaw support during apnoea, whereas the THRIVE arm received jaw support during apnoea and age-specific flow rates. The primary outcome was to demonstrate that children allocated to THRIVE maintain transcutaneous haemoglobin saturation at least twice as long as the expected age-dependent apnoea time in the control group.<strong>Results.</strong> Both study arms (each <span style="font-style:italic;">n</span>=24) were similar in age and weight. The apnoea time was significantly shorter in the control arm: average 109.2 (95% CI 28.8) s in the control arm and 192 s in the THRIVE arm (0–6 months), 147.3 (95% CI 18.9) and 237 s (7–24 months), 190.5 (95% CI 15.3) and 320 s (2–5 yr), and 260.8 (95% CI 37.5) and 430 s (6–10 yr), respectively. Average transcutaneous haemoglobin saturation remained at 99.6% (95% CI 0.2) during THRIVE. Transcutaneous CO<sub>2</sub> increased to a similar extent in both arms, with 2.4 (95% CI 0.5) mm Hg min<sup>−1</sup> for the control arm and 2.4 (95% CI 0.4) mm Hg min<sup>−1</sup> for the THRIVE arm.<strong>Conclusion.</strong> Transnasal humidified rapid-insufflation ventilatory exchange prolongs the safe apnoea time in healthy children but has no effect to improve CO<sub>2</sub> clearance.<strong>Clinical trial registration.</strong> ACTRN12615001319561.</span>
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jELjUt
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Family: Know the drill New Straits Times Online One of my sons had this so often that his tonsils were removed. ... However, for som...
-
UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. J Neurosurg. 2017 Apr 21;:1-9 Authors:...
-
Publication date: Available online 10 May 2017 Source: Journal of Dairy Science Author(s): R.E. Vibart, M. Tavendale, D. Otter, B.H. Schw...
-
Abstract Cerebral and systemic organ microvascular pathologies coexist with human Alzheimer’s disease (AD) neuropathology. In this study, w...
-
Related Articles Developmental control of macrophage function. Curr Opin Immunol. 2017 Dec 13;50:64-74 Authors: Bonnardel J, Guillia...
-
Description A Caucasian boy aged 5 years presented with acute onset of a non-tender, palpable purpuric rash to his lower limbs, preceded by ...
-
Purpose. Sinonasal malignant mucosal melanoma is a rare, aggressive tumour. Nasal obstruction and epistaxis are the most commonly reported s...
-
Abstract Conquering immunosuppression in tumor microenvironments is crucial for effective cancer immunotherapy. It is well known that inte...
-
Abstract: Epidermolytic ichthyosis (EI) is a rare disorder of cornification caused by mutations in KRT1 and KRT10, encoding two suprabasal e...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου